Go Capital et al. invest €2.7m in VitamFero

Existing backers Cap Decisif Management, the Cap Decisif-managed G1J Ile-de-France fund and private investors took part in the round.

Go Capital backed the company via the Ouest Ventures II fund, which raised €21.4m in 2009.

VitamFero will use the funding to further develop its main products, vaccines for ovine toxoplasmosis and bovine neosporosis, and to prepare the products for commercialisation.

Previous funding
VitamFero first received seed funding in September 2009, securing €45,000 from its founders and €202,000 from the Val de France Angels group.

The company completed its first institutional funding round in February 2011, raising €1.1m from Cap Decisif via its €25m Cap Decisif 2 fund.

Company
Founded in 2005 and headquartered in Évry, VitamFero is developing anti-infectious vaccines for animals, with a focus on anti-parasitic vaccines.

The company is currently developing vaccines for ovine and feline toxoplasmosis, as well as bovine neosporosis and cryptosporidiosis.

It has a research and development centre located in Tours and is in the process of opening an additional laboratory in Angers.

People
Pascal Breton is the CEO of VitamFero. Catherine Boule is partner at Cap Decisif. Leila Nicolas is a senior business analyst at Go Capital.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Early-stage
• Healthcare
• France